GlassScriptPhysician profile
Carlos Mella-Picel
NPI 1770713125
$8,646.71
in general payments reported to CMS, 2019-2025
33 companies · $1,403 in 2025
The $1,403 reported for 2025 was more than what 92% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
See the full distribution for Geriatric Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $911 · 2020: $1,409 · 2021: $1,579 · 2022: $1,471 · 2023: $922 · 2024: $951 · 2025: $1,403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,275.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,779.39 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,408.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,008.19 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $705.19 | 2019-2025 | Jardiance |
| Amgen INC. | $670.23 | 2019-2025 | Repatha, Evenity, Prolia |
| Abbvie INC. | $342.55 | 2021-2025 | |
| Corcept Therapeutics | $338.12 | 2025 | Korlym |
| Pfizer INC. | $308.26 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $266.96 | 2022-2025 | |
| Biohaven Pharmaceuticals, INC. | $215.54 | 2021 | |
| Sanofi-Aventis U.S. LLC | $206.61 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $194.88 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $188.29 | 2019-2021 | |
| Glaxosmithkline, LLC. | $150.44 | 2019-2022 | |
| Exact Sciences Corporation | $132.16 | 2023-2025 | Cologuard Collection Kit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.32 | 2019-2024 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $80.47 | 2021-2025 | Rexulti |
| Mylan Specialty L.P. | $71.03 | 2023-2024 | Yupelri |
| Eisai INC. | $62.51 | 2020-2021 | |
| Agios Pharmaceuticals, INC. | $52.24 | 2024-2025 | Pyrukynd |
| Seqirus USA INC | $44.45 | 2024-2025 | Fluad, Flucelvax |
| Avion Pharmaceuticals | $43.55 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.62 | 2021-2025 | Trintellix |
| Arbor Pharmaceuticals, INC. | $37.55 | 2020-2021 | |
| Vbi Vaccine (Delaware) INC. | $32.72 | 2022 | |
| Redhill Biopharma INC. | $28.07 | 2020-2021 | |
| Ardelyx, INC. | $26.10 | 2024 | Ibsrela |
| Biohaven Pharmaceutical Holding Company LTD. | $23.79 | 2022 | |
| Dexcom, INC. | $23.30 | 2023 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $18.08 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.05 | 2019 | |
| Galderma Laboratories, L.P. | $15.06 | 2023 | |
| Phadia US INC. | $14.60 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Mella-Picel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.